Vitals Knowledge Vault

Creatine

9 min read

Creatine Monohydrate

TL;DR

Creatine monohydrate (CrM) is the most evidence-supported ergogenic supplement for high-intensity, short-duration exercise — it reliably increases strength and lean body mass during resistance training. A maintenance dose of 3–5 g/day achieves full muscle saturation within ~3–4 weeks without a loading phase. Creatine has no proven benefit for endurance performance, and its cognitive benefits are confined to specific populations (veg*ns, elderly, sleep-deprived). During loading, expect +0.5–2.0 kg of intracellular water retention — not fat, not muscle, and reversible. Kidney function is unaffected; the creatinine elevation is a pharmacokinetic artifact. All premium forms (Kre-Alkalyn, HCl, ethyl ester) are marketing without evidence.

Why it matters for Vitals

  • Body composition artifacts: Loading creates a real, recoverable ICW artifact (+0.5–2 kg scale weight, sustained +0.5–1 kg long-term). BIA and DEXA are both confounded during the loading window — do not interpret body composition change as genuine muscle gain until 4–6 weeks post-loading.
  • Apple Watch eGFR: Creatinine-based eGFR is artifactually reduced during creatine supplementation. Do not use Apple Watch kidney function estimates for anyone taking creatine. Switch to cystatin C-based eGFR.
  • Recovery scores: Composite recovery scores during loading may be mildly suppressed by osmotic fluid shifts. DOMS weight in composite should be flagged during days 1–7 of loading.
  • HRV: Creatine has minimal direct effect on HRV. Any HRV change during loading is more likely attributable to osmotic shifts or training stress, not creatine per se.
  • Protein floor (Ben’s stack): Ben (65 kg, daily training, Retatrutide week 4) faces compounding appetite/nitrogen-demand risk. Hard floor: 104 g/day; minimum target: 117 g/day; optimal: 130 g/day.
  • Stack safety: No known pharmacodynamic or PK interactions with GHK-Cu or Retatrutide. Adequate hydration is critical with Retatrutide + daily training + creatine stack.

Key Facts

StatusOTC supplement; FDA GRAS; not WADA-banned
ClassErgogenic aid / intracellular osmolyte
Primary mechanismATP buffer via phosphocreatine (PCr/Cr) shuttle; accelerates ADP rephosphorylation during high-intensity contraction
Muscle saturationLoading: 0.3 g/kg/day × 5–7 days → 20–40% above baseline. Maintenance: 3–5 g/day → full saturation in ~21–28 days. Both paths equivalent at 4+ weeks.
Oral bioavailability~99% at 5–10 g doses
Tmax~1.9 h after single 5 g dose; elimination half-life ~3–4 h
Strength effectUpper body WMD = +4.43 kg; lower body WMD = +11.35 kg (PMID:39519498)
FFM with RT+1.14 kg WMD (PMID:39074168, n=694); absent without RT
Older adult LBM+1.37 kg lean mass with RT (PMID:27788767, n=721)
Repeated sprint powerδ = 0.61 mean power improvement
VO2maxSmall negative effect: ES = −0.20 — do not use for aerobic endurance
CognitivePopulation-specific: veg*ns, elderly, sleep-deprived benefit; young omnivores: no effect
Kidney safetyConfirmed safe in healthy adults (PMID:41199218, 2025 BMC Nephrology); creatinine rise is an artifact
FormulationsMicronized CM only; Kre-Alkalyn, HCl, ethyl ester — all not superior or inferior to CM
Hair loss claimDebunked: PMID:40265319 (2025 DB-RCT, n=38, FotoFinder trichogram)
Cramping/dehydration mythDebunked: PMID:18184753
Loading phaseNot required — accelerates saturation only; 3–5 g/day maintenance achieves identical final saturation
DosingMaintenance: 3–5 g/day. Loading (optional): 20 g/day × 5–7 days divided in 4 doses
Main risksGI distress (single large dose); creatinine artifact; ~20–30% non-responders
Evidence levelStrong for strength/power/hypertrophy; moderate for DOMS; low for cognitive (general pop); null/negative for endurance

Mechanism Summary

Phosphocreatine energy shuttle:

Creatine (Cr) is phosphorylated to phosphocreatine (PCr) by mitochondrial creatine kinase (CK) using ATP. PCr travels to sites of high ATP demand (myofibrils, axon terminals) where cytosolic CK rephosphorylates ADP → ATP using PCr as a donor. This buffers ATP where demand exceeds oxidative phosphorylation speed — critical for contractions lasting ~10 s or less, and for repeated high-intensity efforts where PCr partially restores between sets. Skeletal muscle stores ~120–140 mmol/kg dry weight of total creatine.

Cellular hydration — anabolic signal:

Elevated muscle Cr/PCr increases intracellular water content (ICW). This cell swelling activates mTOR, reduces protein catabolism, and may upregulate satellite cell activity — contributing to longer-term hypertrophy independently of training.

Brain energetics:

Brain creatine/PCr supports neural ATP buffering. SLC6A8 (CRT1) transporter at the BBB is rate-limiting and operates near saturation at baseline. Brain total creatine (~4–5 mM) is proportionally smaller and slower to saturate vs. muscle (~35–40 mM). Cognitive benefits emerge primarily under metabolic stress (sleep deprivation, hypoxia) or in low-baseline populations (veg*ns, elderly).

What the current evidence suggests

Athletic performance

Strength: High confidence. Meta-analysis (PMID:39519498, n=500, 22 RCTs): upper body WMD = +4.43 kg, lower body WMD = +11.35 kg vs. placebo. Effect larger in untrained (SMD = 1.06) than trained (SMD = 0.32).

Hypertrophy / LBM: High confidence. Creatine + RT: +1.14 kg fat-free mass (95% CI: 0.69–1.59, PMID:39074168, n=694). Creatine alone without exercise: +0.03 kg — no meaningful effect. Effect requires resistance training as the anabolic driver. DXA-based estimates may overestimate true muscle accretion due to water shifts (PMID:37432300).

Repeated sprint power: Moderate confidence. Mean power improvement δ = 0.61. Performance decrement across repeated sprints not significantly improved — creatine helps each sprint but does not slow the rate of power decline.

Endurance / VO₂max: Null to mildly negative. Do not use creatine for aerobic endurance goals.

DOMS: Moderate confidence. Creatine reduces perceived soreness at 24–48 h post-exercise (d = 0.59–1.15). Effect most consistent when supplementation precedes damaging protocol by ≥7 days.

Cognitive function

Young healthy omnivores: No significant benefit. Null result: PMID:18579168. EFSA 2024 rejected a broad cognitive health claim due to inconsistent evidence.

Specific populations: Supported. Memory: SMD = 0.31 (PMID:39070254, 28 studies). Sleep deprivation recovery: single 0.35 g/kg dose during 21-hour sleep deprivation improved cognitive performance and prevented prefrontal cortex energy failure (PMID:38418482, 2024). Veg*ns and elderly show larger relative benefit due to lower baseline brain creatine.

Kidney safety

Confirmed safe in healthy adults. 2025 BMC Nephrology meta-analysis (PMID:41199218): no evidence of renal harm. 2019 systematic review (PMID:31375416): same conclusion. ISSN Position Stand (PMID:28615996): up to 30 g/day for 5 years not associated with renal dysfunction. Mendelian randomization (PMID:38874125): no causal association between creatine levels and renal dysfunction.

The creatinine artifact: Serum creatinine rises 15–30% during creatine supplementation because creatine spontaneously converts to creatinine at ~1–2% of the total body creatine pool per day. With a larger creatine pool, more creatinine is produced — this is a pharmacokinetic artifact, not kidney damage. True GFR is unchanged.

Debunked myths

  • Hair loss: 2025 DB-RCT (PMID:40265319, n=38, FotoFinder trichogram, 5 g/day × 12 weeks): no difference in DHT, DHT:T ratio, or hair parameters vs. placebo.
  • Cramping/dehydration: PMID:18184753: creatine actually reduced cramping and injury incidence in 219 collegiate football players.
  • Kre-Alkalyn superiority: PMID:22971354: no advantage over CM.
  • Creatine HCl superiority: PMID:11629957: equivalent to CM.
  • Ethyl ester superiority: PMID:19228401: less effective than CM.

Likely wearable / Vitals relevance

DomainSignalConfidenceCaveat
Body weight↑ +0.5–2.0 kg (loading), +0.5–1 kg sustained (ICW)HighExclude from body composition trending during loading
BIA body fat %Falsely decreases during loadingHighICW registered as lean mass
DEXA lean massFalsely increases during loadingHighWater registered as lean tissue
Apple Watch eGFRArtificially reduced by 10–30 mL/minHighUse cystatin C instead
HRV / RMSSDLargely unchangedHighAny change more likely osmotic/training artifact
Resting HRNo significant changeHigh
Sleep (objective)No significant changeHighSubjective quality improves (d=0.81) — real but not wearable-detectable
DOMSMild reduction (d=0.59–1.15)ModerateMore detectable in untrained
VO₂maxSmall negative artifactModerateICW increases body mass → reduces relative aerobic capacity

Risks and Uncertainty

  • Non-responders: ~20–30% of individuals show minimal muscle creatine uptake. If no performance or body composition benefit after 4 weeks, consider this possibility.
  • Loading-phase ICW stress: Days 1–7: rapid intracellular water shift may cause transient bloating, GI discomfort, and mild perceptual “off” feeling.
  • Creatinine artifact: Serum/urine creatinine elevated during supplementation — do not use as kidney health marker. Use cystatin C. Apple Watch eGFR is confounded.
  • VO₂max negative effect: Small but real. Athletes focused on aerobic performance should weigh this.
  • Cognitive oversell: Marketing claims for brain boosting in healthy young adults are not supported. Benefits are narrow and context-dependent.
  • Long-term hair follicle health at loading doses: Does not exist. The 2025 DB-RCT tested only 5 g/day maintenance.
  • Renal screening (age 65+): One-time baseline recommended before initiating. Use cystatin C for ongoing monitoring.
  • Individual genetics: SLC6A8 transporter polymorphisms and 5-alpha reductase activity may modulate individual response — not characterized at population level.
  • Contamination risk: Use Creapure® (German) or third-party tested (Informed Sport, NSF Certified for Sport). FDA does not pre-approve supplements.

Best Stack Context

For Ben’s stack (GHK-Cu 1 mg/day + Retatrutide 0.5 mg/week, 65 kg, daily training):

  • Protein floor: Hard floor 104 g/day; minimum target 117 g/day; optimal 130 g/day. Reta suppresses appetite; creatine shifts ICW; daily training elevates nitrogen turnover. These compounding risk factors can push toward catabolism. Log protein intake daily and alert if <104 g/day.
  • Hydration: Minimum 3 L water/day. Reta suppresses thirst; creatine pulls water intracellularly; daily training = ongoing fluid losses.
  • Protocol: Maintenance start preferred (3–5 g/day). Loading adds GI and hydration demands compounding with Reta. Daily training = consistent muscle uptake opportunity — no need to rush saturation.
  • Timing: Take with largest carbohydrate-containing meal of the day. Insulin modestly enhances muscle creatine uptake. No timing separation from GHK-Cu or Retatrutide required.
  • GI loading risk: If loading, split into 4 doses with meals. GI symptoms more likely on empty stomach with GLP-1 drugs.
  • Renal monitoring: Request cystatin C on next blood panel. Ignore creatinine-based eGFR.
  • Body composition: Do not interpret DEXA or BIA results during first 4–6 weeks of supplementation. Flag as loading artifact.
  • DOMS: Creatine is neutral-to-slightly positive for DOMS. No justification to push harder through soreness.

Inside this hub

The following are kept inline rather than as standalone notes:

  • Full citation tables — provenance layer, not retrieval layer
  • Specific brand/formulation sourcing detail — logistics only
  • Individual DOMS study effect size tables — pooled d range is sufficient
  • SLC6A8 transporter polymorphism nomenclature — individually rare, not currently actionable
  • Creatine loading pseudocode — lives in VitalsSync implementation spec

Graph View

Backlinks